Leap Ebitda vs Total Other Income Expense Net Analysis
LPTX Stock | USD 2.79 0.11 3.79% |
Leap Therapeutics financial indicator trend analysis is infinitely more than just investigating Leap Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Leap Therapeutics is a good investment. Please check the relationship between Leap Therapeutics Ebitda and its Total Other Income Expense Net accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.
Ebitda vs Total Other Income Expense Net
Ebitda vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Leap Therapeutics Ebitda account and Total Other Income Expense Net. At this time, the significance of the direction appears to have pay attention.
The correlation between Leap Therapeutics' Ebitda and Total Other Income Expense Net is -0.71. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Leap Therapeutics, assuming nothing else is changed. The correlation between historical values of Leap Therapeutics' Ebitda and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Leap Therapeutics are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Ebitda i.e., Leap Therapeutics' Ebitda and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | -0.71 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Ebitda
Total Other Income Expense Net
Most indicators from Leap Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.Selling General Administrative is likely to drop to about 8.7 M in 2024. Tax Provision is expected to grow at the current pace this year
Leap Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Leap Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Leap Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.4M | 54.4M | 117.9M | 70.4M | 72.8M | 45.2M | |
Other Current Liab | 3.4M | 3.0M | 4.9M | 4.7M | 5.7M | 3.0M | |
Total Current Liabilities | 8.5M | 7.4M | 10.0M | 11.2M | 12.7M | 9.7M | |
Total Stockholder Equity | (1.7M) | 46.7M | 107.9M | 58.9M | 60.1M | 63.1M | |
Property Plant And Equipment Net | 1.2M | 593K | 495K | 689K | 262K | 444.1K | |
Net Debt | (2.9M) | (51.5M) | (114.4M) | (64.8M) | (70.4M) | (66.9M) | |
Retained Earnings | (195.2M) | (223.0M) | (263.6M) | (318.2M) | (399.6M) | (379.6M) | |
Accounts Payable | 4.6M | 2.7M | 4.2M | 5.7M | 6.5M | 6.8M | |
Cash | 3.9M | 52.1M | 114.9M | 65.5M | 70.6M | 38.1M | |
Non Current Assets Total | 3.2M | 2.1M | 1.0M | 2.4M | 1.2M | 1.9M | |
Non Currrent Assets Other | 1.9M | 1.3M | 383K | 1.7M | 966K | 1.3M | |
Cash And Short Term Investments | 3.9M | 52.1M | 114.9M | 65.5M | 70.6M | 42.0M | |
Net Receivables | 185K | 73K | 1.2M | 2.1M | 771K | 1.0M | |
Common Stock Total Equity | 15K | 24K | 60K | 88K | 101.2K | 106.3K | |
Common Stock Shares Outstanding | 2.3M | 5.9M | 8.6M | 11.3M | 20.4M | 21.5M | |
Liabilities And Stockholders Equity | 7.4M | 54.4M | 117.9M | 70.4M | 72.8M | 45.2M | |
Non Current Liabilities Total | 3.4M | 711K | 348K | 37K | 262K | 0.0 | |
Other Current Assets | 165K | 130K | 769K | 351K | 183K | 284.3K | |
Other Stockholder Equity | 193.3M | 270.2M | 371.6M | 376.8M | 459.6M | 482.6M | |
Total Liab | 9.2M | 7.7M | 10.0M | 11.5M | 12.7M | 8.8M | |
Property Plant And Equipment Gross | 1.2M | 593K | 495K | 689K | 483K | 464.4K | |
Total Current Assets | 4.2M | 52.3M | 116.9M | 68.0M | 71.6M | 43.3M | |
Accumulated Other Comprehensive Income | 76K | (579K) | (267K) | 128K | 106K | 100.7K | |
Common Stock | 24K | 60K | 88K | 99K | 26K | 27.3K | |
Net Tangible Assets | (1.7M) | 46.7M | 107.9M | 58.9M | 67.7M | 71.1M | |
Other Assets | 2.1M | 2.0M | 542K | 1.7M | 2.0M | 1.5M | |
Property Plant Equipment | 1.2M | 65K | 36K | 689K | 792.4K | 832.0K | |
Capital Surpluse | 162.4M | 193.3M | 270.2M | 371.6M | 427.4M | 448.8M | |
Deferred Long Term Liab | 162K | 831K | 345K | 576K | 518.4K | 442.1K | |
Non Current Liabilities Other | 3.4M | 159K | 348K | 37K | 33.3K | 31.6K | |
Retained Earnings Total Equity | (153.5M) | (195.2M) | (223.0M) | (263.6M) | (237.2M) | (249.1M) | |
Net Invested Capital | (1.7M) | 46.7M | 107.9M | 58.9M | 60.1M | 45.9M | |
Net Working Capital | (4.2M) | 44.9M | 106.9M | 56.7M | 58.9M | 46.5M | |
Capital Stock | 24K | 60K | 88K | 99K | 26K | 24.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.